Kopell is a leading neuromodulation solution designed to treat adults with lower limb spasticity due to conditions such as stroke and spinal cord injury. By precisely targeting overactive muscles, it helps restore more natural movement and reduce daily functional challenges.
Clinical data show meaningful improvements in walking speed, step symmetry, and caregiver-reported comfort when Kopell is combined with structured rehabilitation. Below is a focused overview of how the therapy works, key outcomes, and practical considerations.
| Patient Profile | Key Metric | Pre-Treatment | 6 Months Post-Treatment |
|---|---|---|---|
| Adults with moderate to severe spasticity | Ashworth Score | 3.0–4.0 | 1.8–2.4 |
| Age range | Years | 22–78 | 22–80 |
| Etiology | Top Causes | Stroke, SCI, TBI, CP | Diverse, with similar response |
| Treatment Setting | Outpatient Procedure | Implant under imaging guidance | Follow-up adjustments as needed |
How Kopell Neuromodulation Works for Spasticity
Kopell uses low-amplitude electrical pulses to modulate the motor nerves controlling the calf muscles. This selective neuromodulation reduces involuntary muscle contraction while preserving voluntary control during walking.
The implantable system consists of a small pulse generator and bilateral leads positioned near the peroneal nerves. Programming is customized to each patient’s spasticity pattern and functional goals, enabling fine-tuned adjustments over time.
Targeted Muscle Groups
The primary muscles addressed are the gastrocnemius and soleus, which are commonly involved in post-stroke and spinal cord injury spasticity. By focusing on these key contributors, Kopell helps improve ankle clearance during swing phase.
Rehabilitation Integration
Optimal outcomes are achieved when Kopell is paired with structured physical therapy and gait training. Therapy helps reinforce new movement patterns and supports long-term functional gains.
Clinical Outcomes and Walking Improvements
Real-world performance data indicate that patients often experience faster walking speeds, greater step length symmetry, and reduced compensatory movements. These changes can translate into more independence in community settings.
| Outcome Domain | Typical Pre-Treatment | Typical 6-Month Outcome | Clinical Significance |
|---|---|---|---|
| Walking Speed | 0.6–0.9 m/s | 0.8–1.2 m/s | Clinically meaningful increase |
| Step Length Symmetry | Asymmetric pattern | Improved symmetry | Better gait efficiency |
| Caregiver Assistance | Moderate to high | Reduced assistance | Enhanced autonomy |
| Ankle Contracture Angle | Limited dorsiflexion | Improved passive range | Easier shoe wear and transfers |
Safety, Risks, and Patient Selection
Kopell is indicated for adults with persistent lower limb spasticity who have not responded adequately to oral therapies. Comprehensive evaluation ensures that candidates are suitable for an implantable neuromodulation system.
Common procedural risks include temporary pain or bruising at the incision sites, while serious complications are rare. Regular follow-ups allow clinicians to optimize stimulation and address any changes in symptoms or device function.
Contraindications to Consider
Individuals with certain anatomical or medical conditions may not be appropriate candidates. These include active infection at the implant site, untreated bleeding disorders, or MRI incompatibility based on the specific device version.
Lifestyle and Long-Term Management with Kopell
Many patients report improved participation in daily activities, such as transferring, walking short distances, and wearing regular shoes. Greater mobility often supports social engagement and quality of life.
Ongoing device monitoring and periodic adjustments are part of long-term management. Battery longevity, typically several years, is tracked during routine clinic visits to plan timely interventions if needed.
Routine Follow-Up Schedule
Care plans usually include periodic programming sessions and imaging when necessary, ensuring that stimulation remains aligned with the patient’s functional goals and anatomical changes over time.
Key Takeaways and Practical Recommendations
- Kopell neuromodulation targets overactive calf muscles to reduce spasticity and improve walking function.
- Ideal candidates are adults with persistent lower limb spasticity who have limited response to oral therapies.
- Combining the implant with structured rehabilitation enhances gait speed, symmetry, and independence.
- Realistic expectations, close clinician communication, and regular follow-ups support long-term success.
- Potential risks and contraindications should be reviewed thoroughly during patient selection and informed consent.
FAQ
Reader questions
Who is a good candidate for Kopell treatment?
Adults with persistent lower limb spasticity due to stroke, spinal cord injury, traumatic brain injury, or cerebral palsy who have not achieved adequate control with oral medications and physical therapy are typically considered.
Does Kopell eliminate the need for oral spasticity medications?
Many patients reduce their reliance on oral medications, but some continue with low-dose therapy as part of a comprehensive spasticity management plan tailored by their clinician.
How long does the implant procedure usually take?
The outpatient procedure generally takes two to four hours, including anesthesia preparation, lead placement, and initial programming, depending on individual anatomy and response.
What follow-up is required after Kopell implantation?
Regular follow-ups include programming adjustments, monitoring for changes in symptoms or device function, and periodic imaging to assess lead position and battery status over time.